EMAIL THIS PAGE TO A FRIEND

European journal of medicinal chemistry

A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.


PMID 23454517

Abstract

A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B). The results demonstrate that most of the synthesised compounds exhibit high inhibitory activity. Among these compounds, compound 8g provided a good balance of activity towards all targets (with IC50 values of 22.6 nM, 9.37 nM, 0.3724 μM, and 0.1810 μM for AChE, BuChE, MAO-A and MAO-B, respectively). These results indicated that 8g has the potential to be a multi-functional candidate for Alzheimer's disease.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

S0360090 (RS)-Selegiline hydrochloride, European Pharmacopoeia (EP) Reference Standard
C13H17N · HCl